TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Ondine Biomedical, Inc. ( (GB:OBI) ).
Ondine Biomedical Inc. announced significant findings from a study conducted by the University of Sherbrooke, demonstrating that their Steriwave nasal photodisinfection therapy significantly reduces surgical site infections (SSIs) in spine surgery patients. The study, presented at the Canadian Spine Society’s annual conference, showed a 78.8% reduction in SSIs and a 30% decrease in hospital stays for patients treated with Steriwave. These results highlight the potential of Steriwave to improve patient outcomes and reduce healthcare costs, reinforcing its value as an innovative solution in infection prevention.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection, to prevent and treat infections, including those caused by antibiotic-resistant bacteria. The company offers a patented technology that provides a safe, rapid, and effective alternative to traditional antibiotics.
YTD Price Performance: 11.43%
Average Trading Volume: 255,257
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £39.39M
See more data about OBI stock on TipRanks’ Stock Analysis page.